Evidence map›Paper›PMID 37407040›Full record

ArticleBMJ open2023

Vitamin insufficiency after surgery for oesophagogastric neoplasms: a study protocol for a prospective intervention study.

Ariadne L van der Velden, Thomas A Vermeer, Evert-Jan G Boerma, Eric Hj Belgers, Jan Hmb Stoot, Mathie Pg Leers, Meindert N Sosef, Guy Hej Vijgen

Registry-linked trialAbstract read
In one paragraph

Article in BMJ open, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05281380 (Vitamin Insufficiency After Surgery for Esophagogastric Neoplasms), which is not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05281380 naunknown statusnot on this map

Vitamin Insufficiency After Surgery for Esophagogastric Neoplasms: a Prospective Intervention Study

TypeinterventionalSponsorZuyderland Medisch CentrumRan2021 to 2024Enrolled248ConditionsEsophageal Cancer, Gastric Cancer, Vitamin Disease, Quality of LifeArmsGIKAVI
3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Trial
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Ariadne L van der VeldenDepartment of Surgery, Zuyderland Medical Centre, Heerlen, The Netherlands l.vandervelden@zuyderland.nl.ORCID 0000-0003-0351-2581
Thomas A VermeerDepartment of Surgery, Zuyderland Medical Centre, Heerlen, The Netherlands.
Evert-Jan G BoermaDepartment of Surgery, Zuyderland Medical Centre, Heerlen, The Netherlands.
Eric Hj BelgersDepartment of Surgery, Zuyderland Medical Centre, Heerlen, The Netherlands.
Jan Hmb StootDepartment of Surgery, Zuyderland Medical Centre, Heerlen, The Netherlands.
Mathie Pg LeersClinical Chemistry & Hematology, Zuyderland Medical Centre, Heerlen, The Netherlands.ORCID 0000-0001-5186-5600
Meindert N SosefDepartment of Surgery, Zuyderland Medical Centre, Heerlen, The Netherlands.
Guy Hej VijgenDepartment of Surgery, Zuyderland Medical Centre, Heerlen, The Netherlands.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionOesophageal cancer (EC) and gastric cancer (GC) are among the top 10 cancers worldwide. Both diseases impact the nutritional status of patients and their Quality of Life (QoL). Preoperative malnutrition is reported in 42%-80%. However, studies investigating postoperative nutritional status are limited, and postoperative identification and treatment of micronutrient and macronutrient deficiencies are currently lacking in (inter-)national guidelines. The aim of this study is to identify and target micronutrient deficiencies after surgery for oesophagogastric neoplasms.

methodsThis is a single-centre prospective intervention trial performed in Zuyderland Medical Centre. 248 patients who underwent oesophagectomy (n=124) or (sub)total gastrectomy (n=124) from 2011 until 2022 will be included. Both groups will receive Calcium Soft Chew D3 and a multivitamin supplement (MVS) specifically developed according to the type of operation patients underwent; the oesophagectomy group will receive Multi-E and the gastrectomy group will receive Multi-G. The MVSs will be taken once daily and Calcium Soft Chew D3 two times per day. Supplementation will start after baseline measurements. At baseline (T0), blood withdrawal for micronutrient analysis and faecal elastase-1 analysis for exocrine pancreatic insufficiency (EPI) will be performed. Additionally, patients will receive questionnaires regarding QoL and dietary behaviour. After 180 days of supplementation (T1), baseline measurements will be repeated, and the supplement tolerance questionnaire will be completed. Measurements will also be conducted after 360 days (T2) and after 720 days (T3) of supplementation. The main study parameter is micronutrient deficiency (yes/no) for all measurements. Secondary parameters include occurrence of EPI (n, %), diarrhoea (n, %), steatorrhoea (n, %) or bloating (n, %), time between surgery and start of supplementation (mean in months), and QoL at all time points. ETHICS AND DISSEMINATION: The study was approved by the Zuyderland Medical Centre Ethics Committee, Heerlen, the Netherlands. The findings will be disseminated through scientific congresses and in peer-reviewed journals. TRIAL REGISTRATION NUMBER: NCT05281380.

Indexed as

Esophageal NeoplasmsVitaminsCalciumCalcium, DietaryHumansProspective StudiesQuality of LifeCalciumCalcium, DietaryVitaminsgastrointestinal tumoursmalabsorptionnutritional supportoesophageal diseasesurgery

Identifiers

PMID37407040
PMCPMC10335568

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.